A5061372203- Hematopoietic Stem Cell Transplantation
- Acute Myeloid Leukemia Research
- Renal Transplantation Outcomes and Treatments
- Cytomegalovirus and herpesvirus research
- Acute Lymphoblastic Leukemia research
- T-cell and B-cell Immunology
- Multiple Myeloma Research and Treatments
- Protein Degradation and Inhibitors
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Chronic Myeloid Leukemia Treatments
- Chronic Lymphocytic Leukemia Research
- Frailty in Older Adults
- Polyomavirus and related diseases
- Neutropenia and Cancer Infections
- Nutrition and Health in Aging
- Lymphatic System and Diseases
- Mycobacterium research and diagnosis
- Pneumocystis jirovecii pneumonia detection and treatment
- Liver Disease and Transplantation
- Diagnosis and Treatment of Venous Diseases
- Viral-associated cancers and disorders
- Liver Disease Diagnosis and Treatment
- Multiple Sclerosis Research Studies
- Telemedicine and Telehealth Implementation
- Genital Health and Disease
Hospital Universitari de Vic
2025
Hospital Clínic de Barcelona
2020-2025
Consorci Institut D'Investigacions Biomediques August Pi I Sunyer
2021-2025
Universitat de Barcelona
2024-2025
Carfilzomib, lenalidomide and dexamethasone (KRd) is still a widely used treatment option for patients with relapsed / refractory multiple myeloma (RRMM). However, there limited real-world evidence. Here we evaluated the efficacy safety of KRd in RRMM treated following standard clinical practice hospitals Catalan region. This was retrospective, observational study. The objective response rate (ORR) according to IMWG criteria primary endpoint. Secondary endpoints included progression-free...
Summary European LeukemiaNet refined their risk classification of acute myeloid leukaemia (AML) in 2022 (ELN 2022) according to the two new classifications published same year. We have retrospectively assessed prognostic value ELN 120 AML patients undergoing allogeneic haematopoietic cell transplantation (allo‐HCT), including 99 first complete response (CR1) from 2011 2021 our centre. Adverse (Adv) presented inferior outcome terms overall survival (OS) and leukaemia‐free (LFS) (OS [ p =...
This study investigates early cardiac events (ECEs) occurring during the first 180 days after allogeneic hematopoietic cell transplant (allo-HCT) in 416 adults receiving posttransplant cyclophosphamide (PTCY) (n = 258) or not PTCY 158). Total body irradiation (TBI) was given to 133 (31.9%) patients, of whom 111 (83.4%) received TBI combined with PTCY. The day +180 cumulative incidence function (CIF) ECEs 8.4%, heart failure 13) and pericardial complications 11) being most prevalent...
PTCY 50 mg/kg/day on days +3/+4 is an excellent strategy to prevent GVHD. However, its use associated with adverse outcomes such as delayed engraftment, increased risk of infection, and cardiac complications. This pilot study evaluates the efficacy toxicity a reduced dose (40 mg/kg/day) combined tacrolimus in 22 peripheral blood HLA-matched alloHSCT patients. At day +100, cumulative incidences grade II–IV III–IV acute GVHD were 18.2% 4.5%, respectively. No IV or steroid-refractory disease...
Chronic graft-vs-host disease (cGvHD) is a severe immune-mediated complication that affects patients following allogeneic hematopoietic stem cell transplantation (allo-HSCT). Oral manifestations of cGvHD, such as ulcers and mucosal inflammation, significantly impair quality life often require long-term treatment. Existing therapies provide limited relief, prompting the exploration new approaches, including use autologous platelet lysate (PL) gel for its regenerative properties. This...
Cholemic nephropathy is an overlooked cause of acute kidney injury (AKI) in patients with advanced cirrhosis and high bilirubin plasma levels (usually above 20mg/dl), due to bile acid deposition the kidneys. Those deposits have been hypothesized tubular injury. It has no standardized diagnostic criteria or therapeutic strategies. We present a series fifteen severe cholemic AKI, diagnosed by microscopic urinary cast visualization after excluding treating other causes AKI. Bilirubin removal...
Background/Objectives: This study evaluated infectious complications and immune reconstitution in 253 adults undergoing peripheral blood allogeneic hematopoietic cell transplantation (allo-HCT) with post-transplant cyclophosphamide (PTCY)-based GVHD prophylaxis. Methods: Patients received grafts from HLA-matched donors (47.4%), mismatched unrelated (MMUD, 33.2%), or haploidentical (19.4%). Results: The estimated 2-year non-relapse mortality (NRM) was 11.8%, 26.4%, 22.4%, respectively (p =...
Abstract Background and Objectives Clinical efficacy safety of pathogen‐reduced platelet concentrates (PR‐PCs) concerning bleeding prevention are still debated despite conclusive real‐world data from multiple countries where PR‐PCs transfused routinely. We performed a meta‐analysis randomized controlled trials (RCTs) comparing the clinical conventional components (PCs) prepared with amotosalen/ultraviolet A light (INTERCEPT concentrate [I‐PC]) or riboflavin/ultraviolet (Mirasol [M‐PC])...
The use of post-transplantation cyclophosphamide (PTCY) for graft-versus-host disease (GHVD) prevention is becoming prevalent in the transplantation community when HLA-identical sibling and 10/10 HLA-matched (MUD) 9/10 mismatched unrelated donors are selected alloHSCT. However, reported evidence on outcomes from elderly patients receiving PTCY-containing GVHD prophylaxis remains limited. This study aims to compare PTCY- tacrolimus (TK) conventional aged >50 years undergoing peripheral blood...
In recent years, important epidemiologic changes have been described in hematopoietic stem cell transplantation (HSCT) recipients with bloodstream infection (BSI), increases gram-negative bacilli and multidrug resistant (MDR) bacilli. These linked to a worrisome increase mortality. We aimed define the risk factors for mortality of HSCT patients experiencing BSI. All episodes BSI between 2008 2017 were prospectively collected. Multivariate analyses performed. A total 402 documented 293 who...
Despite emerging molecular information on chronic myelomonocytic leukemia (CMML), patient outcome remains unsatisfactory and little is known about the transformation to acute myeloid (AML). In a single-center cohort of 219 CMML patients, we explored potential correlation between clinical features, gene mutations, treatment regimens with overall survival (OS) clonal evolution into AML. The most commonly detected mutations were TET2, SRSF2, ASXL1, RUNX1. Median OS was 34 months varied...
This study investigates the incidence and predictors for bacterial bloodstream infection (BSI) in 330 adults undergoing allo-HCT, explores effect of post-transplantation cyclophosphamide (PTCY) on probability presenting this complication. All patients received levofloxacin during aplastic phase. Only first episode BSI was counted as an event. Patients were classified into 2 groups: PTCY-based (n = 200) versus other prophylaxis 130). One hundred twenty-four diagnosed with a BSI, most them 30...
The impact of infused CD34+ cell dose on outcomes after allogeneic hematopoietic stem transplantation (alloHSCT) using standard graft-versus-host disease (GVHD) prophylaxis remains controversial. Information this subject is scarce for alloHSCT high-dose post-transplantation cyclophosphamide (PTCy). We aimed to assess the effect in peripheral blood (PBSC) grafts outcome PTCy-based GVHD prophylaxis. To do so, we conducted a single-center retrospective analysis 221 consecutive adult patients...
Summary Recently modified diagnostic criteria for chronic myelomonocytic leukaemia (CMML) have lowered the cut‐off absolute monocytosis. In largest series to date, we analysed 313 CMML patients, including 104 with oligomonocytic (OM)‐CMML. Five‐year survival was longer OM‐CMML than other patients ( p < 0.001). Multivariate analysis identified as a favourable prognostic factor (HR 0.58; = 0.002). The 5‐year cumulative incidence of progression classical 47%. Older age and transfusion...